Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders

Leukemia. 2006 Jun;20(6):1181-3. doi: 10.1038/sj.leu.2404214.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Clone Cells / pathology
  • Female
  • Follow-Up Studies
  • Hematopoietic Stem Cells / pathology*
  • Humans
  • Hydroxyurea / therapeutic use
  • Interferon-alpha / therapeutic use
  • Janus Kinase 2
  • Middle Aged
  • Mutation
  • Protein-Tyrosine Kinases / genetics*
  • Proto-Oncogene Proteins / genetics*
  • Thrombocythemia, Essential / diagnosis
  • Thrombocythemia, Essential / drug therapy
  • Thrombocythemia, Essential / genetics*
  • Thrombocythemia, Essential / pathology*
  • Treatment Outcome

Substances

  • Interferon-alpha
  • Proto-Oncogene Proteins
  • Protein-Tyrosine Kinases
  • JAK2 protein, human
  • Janus Kinase 2
  • Hydroxyurea